Analysts/Institutional Investor Meet/Con. Call Updates

27th July, 2026 (1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers Exchange Plaza, 5th floor Dalal Street Plot no. C/1, G Block Mumbai - 400 001 Bandra Kurla Complex Bandra (East), Mumbai - 400 051 Scrip Code: 500087 Scrip Symbol: CIPLA (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II L-1840 Luxembourg Sub: Q1 FY27 - Earnings Call Transcript Dear Sir/Madam, We are enclosing herewith a copy of the transcript of the Company’s Q1 FY27 earnings conference call held on 23rd July, 2026. The transcript is also available on the Company’s website at https://www.cipla.com/sites/default/files/Cipla-Earnings-Jul23-2026.pdf. Kindly take the above information on record. Thanking you, Yours faithfully, For Cipla Limited Rajendra Chopra Company Secretary Encl: as above Prepared by: Simona Dsouza Cipla Ltd. Regd. Office - Cipla House, Peninsula Business Park, Ganpatrao Kadam Marg, Lower Parel, Mumbai-400 013, India P +91 22 41916000 W www.cipla.com E-mail contactus@cipla.com Corporate Identity Number L24239MH1935PLC002380 “Cipla Limited Q1 & FY27 Earnings Conference Call” July 23, 2026 MANAGEMENT: MR. ACHIN GUPTA – MANAGING DIRECTOR AND GLOBAL CHIEF EXECUTIVE OFFICER – CIPLA LIMITED MR. ASHISH ADUKIA – GLOBAL CHIEF FINANCIAL OFFICER – CIPLA LIMITED MS. DIKSHA MAHESHWARI – HEAD INVESTOR RELATIONS – CIPLA LIMITED Page 1 of 18 Cipla Limited July 23, 2026 Moderator: Ladies and gentlemen, good day, and welcome to Cipla Limited Q1 and FY27 Earnings Conference Call. We have with us today Mr. Achin Gupta, MD and Global CEO; Mr. Ashish Adukia, Global CFO; Ms. Diksha Maheshwari, Head of Investor Relations. As a reminder, all participant lines will be in the listen-only mode and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star, then zero on your touch- tone phone. Please note that this conference is being recorded. I now hand the conference over to Ms. Diksha Maheshwari Head of Investor Relations. Thank you, and over to you, ma'am. Diksha Maheshwari: Thank you, Danish. Good afternoon, and a very warm welcome to Cipla's Q1 FY27 Earnings Call. I'm Diksha Maheshwari from the Investor Relations team at Cipla. Let me draw your attention to the fact that on this call, our discussion will include certain forward-looking statements, which are predictions, projections or other estimates about future events. These estimates reflect our management's current expectations of the future performance of the company. Please note that these estimates involve several risks and uncertainties that could cause our actual results to differ materially from what is expressed or implied. Cipla does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new confirmations, future events or otherwise. I hope you have received the investor presentation that we have posted on our website. I would like to request Achin to take over. Achin Gupta: Thank you, Diksha. Good afternoon to all of you, and we appreciate you joining for our Q1 FY27 earnings call. I'm delighted to share that we have delivered the highest ever Q1 revenue with revenues of INR7,100 crores in this Q1. Achieving a record first quarter provides a strong start to the year. It reinforces the resilience of our business fundamentals, the diversified nature of our business, and it strengthens our confidence in sustaining long-term growth. Coming to the business-wise performance. Our One India business achieved its highest ever quarterly revenue with 12% Y-o-Y growth, reflecting a strong performance across key therapies and underscoring the strength of our franchise in the IPM. Within this, the branded prescription business continued to witness strong momentum across chronic portfolio, delivering a market-leading growth of 15.4% during the quarter as per IQVIA data. Key therapies registered strong double-digit growth. Respiratory grew at 15%; Anti-diabetes; 43%; Cardiac 20%; and Urology at double-digit as per the IQVIA data for the quarter ended June 26. This performance was driven by a strong volume expansion, sustained brand strength, focused field execution and continued momentum from new product launches. Page 2 of 18 Cipla Limited July 23, 2026 Our overall chronic mix strengthened this quarter to 60.4% Y-o-Y. We added 2 new brands to the INR100-plus crores club, taking our total to 33. And our presence in the IPM top 300 brands remains strong with 23 brands, reinforcing the depth and resilience of our portfolio. Foracort, which is our flagship inhalation brand, continued to strengthen its leadership position as the number 1 respiratory brand in the IPM while sustaining its status as INR1,000-plus crores franchise. Cipla continues to be the largest pharma company in terms of volume and the only player with 2 billion-plus unit sales in IPM as per IQVIA MAT June '26. Our new launch momentum also remains strong with a number of targeted introductions across key chronic specialty and wellness segments. In respiratory, we strengthened our portfolio with Duolin Synchrobreathe, a breath-actuated inhalation platform designed to enhance ease of use and adherence, and Bilafav M for the management of allergic rhinitis and associated symptoms. In the obesity segment, following our entry into the segment through our collaboration with Eli Lilly for Yurpeak in the previous quarter, the brand has continued to witness encouraging traction and delivered a strong performance during the quarter. In immunology, we launched UPADACIP, significantly strengthening our presence in chronic inflammatory and autoimmune disorders and enhancing our ability to address patient needs in a rapidly evolving specialty segment. Additionally, Byefilm, which is our nasal hygiene range, broadened our supportive care and wellness portfolio. Collectively, these launches reinforce our commitment to addressing evolving patient needs and deepen our presence in high opportunity chronic therapy areas and further strengthen the breadth and competitiveness of our portfolio. On the trade generic side, our business delivered a healthy growth during the quarter on the back of vigorous execution in distribution and new product launches. Expanding our portfolio remains a key growth driver with 3 new launches this quarter, addressing specific patient needs. Our Consumer Health business continued its upward trajectory with Nicotex, Omnigel and Cipladine consolidating their respective number 1 positions in the segment. The business is driving healthy secondary growth and actively exploring opportunities to invest in products and channels to further expand our distribution. Operating profitability improved during the quarter, reflecting the strength and scalability of the consumer health. In North America, we delivered quarterly revenue of 162 million. Cipla continues to hold the number 1 position in the overall U.S. Albuterol MDI market this quarter with our market share standing at 21% as per IQVIA data for the week ending June 2026. One key highlight for the quarter was the successful launch of generic Ventolin in the U.S. following regulatory approval, which was received last quarter. We have commenced commercial shipments with volumes expected to increase as the supply scales up. During the Page 3 of 18 Cipla Limited July 23, 2026 quarter, we further strengthened our portfolio with the launch of Nintedanib and Dapagliflozin in addition to some of the more recent launches like Liraglutide, which is expanding our presence in high-growth therapy areas and advancing the execution on our pipeline. Looking ahead, we expect North America business to continue its sequential growth trajectory during the year supported by the upcoming product launches and continued commercial execution. More details on the U.S. pipeline. As [Showing first 8,000 characters — download PDF for full document]